FDA
approval
· 2018-11-12
FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
Summary
The FDA approved a supplemental application for Ocrevus (ocrelizumab) submitted by Genentech, Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for OCREVUS (OCRELIZUMAB)